Health Care & Hospital Law,
Civil Litigation
May 26, 2021
Plaintiffs close false advertising case against drugmakers
The people, represented by four prosecuting agencies, say drug companies paid opinion leaders, patient groups and researchers to endorse the use of opioids for the treatment of noncancer pain despite the FDA only approving their use for cancer pain.




Wrapping up their $50 billion false advertising case Tuesday in Orange County, the people played deposition tapes of drug company employees who marketed opioids as a treatment for noncancer pain, a use not approved by the Food and Drug Administration, the state's attorneys say.
Cephalon Inc., one of the pharmaceutical companies accused of fueling the state's opioid crisis by deceptively marketing its products, paid $425 million a...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In